|Description||Varenicline(CP 526555; Champix; Chantix) is a prescription medication used to treat smoking addiction. As a partial agonist it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Through these mechanisms Varenicline(CP 526555; Champix; Chantix) can assist some patients to quit smoking.|
|B0084-064059||1 g||$499||In stock|
|Synonyms||CP 526555; Champix; Chantix; CP526555; CP-526555|
The hydrochloride salt form of Procyclidine which has been found to be a muscarinic antagonist that could be effective against Parkinson's disease and some rela...
Mecamylamine hydrochloride is a non-competitive nicotinic acetylcholine receptor antagonist with preferential activity at the α3β4 subtype (IC50 = 90-640 nM) co...
EVP-6124 is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs). It shows selectivity for α7 nAChRs and did not activate or inhibi...
5-Iodo-A-85380 dihydrochloride is the dihydrochloride salt of 5-Iodo-A-85380, which is a highly potent and subtype-selective agonist for α4β2 and α6β2 nicotinic...
CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR). It was shown to induce positive modulation of acetylcholine (A...
A 844606 is a selective α7 nicotinic acetylcholine receptor (nAChR) partial agonist (EC50 = 1.4 and 2.2 μM at human and rat receptors, respectively). It has no ...
3-Bromocytisine has been found to be an α4β4, α4β2 and α7 nACh receptor agonist.
GAT107 is an allosteric agonist (EC50 value 28 μM) and positive allosteric modulator (PAM) of α7 nicotinic acetylcholine receptors (nAChR). GAT107 is the bioact...